| ||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
Search results for: "C"
Results 141 - 150 of 959 shown below 
|
||||||||
|
||||||||
|
||||||||
|
||||||||
| capecitabine D C Talbot, V Moiseyenko, S Van Belle, S M O'Reilly, E Alba Conejo, S Ackland, P Eisenberg, D Melnychuk, T Pienkowski, H-U Burger, S Laws and B Osterwalder Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines doi:10.1038/sj.bjc.6600261 Abstract | Full article | PDF C J Twelves and J Cassidy Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? doi:10.1038/sj.bjc.6600341 Abstract | Full article | PDF R M Mader, C Schrolnberger, B Rizovski, M Brunner, C Wenzel, G Locker, H G Eichler, M Mueller and G G Steger Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer doi:10.1038/sj.bjc.6600809 Abstract | Full article | PDF K Brickell, D Porter and P Thompson Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports doi:10.1038/sj.bjc.6601137 Abstract | Full article | PDF R-D Hofheinz, J T Hartmann, A Willer, K Oechsle, G Hartung, U Gnad, S Saussele, S Kreil, C Bokemeyer, R Hehlmann and A Hochhaus Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial advance online publication, 2004-07-06 00:00:00.000; doi:10.1038/sj.bjc.6602025 Abstract | Full article | PDF S Rao, D Cunningham, T Price, M E Hill, P J Ross, N Tebbutt, A R Norman, J Oates and P Shellito Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer advance online publication, 2004-07-20 00:00:00.000; doi:10.1038/sj.bjc.6602039 Abstract | Full article | PDF J S Waters, C Moss, L Pyle, M James, S Hackett, R A'Hern, M Gore and T Eisen Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma advance online publication, 2004-10-26 00:00:00.000; doi:10.1038/sj.bjc.6602209 Abstract | Full article | PDF R Hitt, A Jimeno, M Rodríguez-Pinilla, J L Rodríguez-Peralto, J M Millán, A López-Martín, A Brandariz, C Peña and H Cortés-Funes Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors advance online publication, 2004-12-14 00:00:00.000; doi:10.1038/sj.bjc.6602275 Abstract | Full article | PDF H J Kang, H M Chang, T W Kim, M-H Ryu, H J Sohn, J H Yook, S T Oh, B S Kim, J-S Lee and Y-K Kang Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy advance online publication, 2005-01-18 00:00:00.000; doi:10.1038/sj.bjc.6602336 Abstract | Full article | PDF J P Delord, J Y Pierga, V Dieras, F Bertheault-Cvitkovic, F L Turpin, F Lokiec, I Lochon, E Chatelut, P Canal, R Guimbaud, D Mery-Mignard, X Cornen, Z Mouri and R Bugat A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours advance online publication, 2005-03-01 00:00:00.000; doi:10.1038/sj.bjc.6602354 Abstract | Full article | PDF S Lorenzen, J Duyster, C Lersch, S von Delius, M Hennig, R Bredenkamp, C Peschel and F Lordick Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial advance online publication, 2005-06-07 00:00:00.000; doi:10.1038/sj.bjc.6602645 Abstract | Full article | PDF G Chong, J L B Dickson, D Cunningham, A R Norman, S Rao, M E Hill, T J Price, J Oates and N Tebbutt Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan advance online publication, 2005-08-09 00:00:00.000; doi:10.1038/sj.bjc.6602733 Abstract | Full article | PDF J G Kim, S K Sohn, D H Kim, J H Baek, S B Jeon, Y S Chae, K B Lee, J S Park, J H Sohn, J C Kim and I K Park Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck advance online publication, 2005-10-25 00:00:00.000; doi:10.1038/sj.bjc.6602849 Abstract | Full article | PDF C Rothermundt, R Hubner, T Ahmad, I Gibbens, C Keyzor, T Habeshaw, S Kaye and M Gore Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial advance online publication, 2005-11-22 00:00:00.000; doi:10.1038/sj.bjc.6602879 Abstract | Full article | PDF Y H Park, B-S Kim, B-Y Ryoo and S H Yang A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer advance online publication, 2006-03-21 00:00:00.000; doi:10.1038/sj.bjc.6603046 Abstract | Full article | PDF J Feliu, A Salud, P Escudero, L Lopez-Gómez, M Bolaños, A Galán, J-M Vicent, A Yubero, F Losa, J De Castro, M Á de Mon, E Casado and M González-Barón XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer advance online publication, 2006-03-21 00:00:00.000; doi:10.1038/sj.bjc.6603047 Abstract | Full article | PDF R Sharma, L Rivory, P Beale, S Ong, L Horvath and S J Clarke A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer advance online publication, 2006-03-21 00:00:00.000; doi:10.1038/sj.bjc.6603049 Abstract | Full article | PDF G Klautke, U Küchenmeister, T Foitzik, K Ludwig, F Prall, E Klar and R Fietkau Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study advance online publication, 2006-03-21 00:00:00.000; doi:10.1038/sj.bjc.6603053 Abstract | Full article | PDF J Cassidy, J-Y Douillard, C Twelves, J J McKendrick, W Scheithauer, I Bustová, P G Johnston, K Lesniewski-Kmak, S Jelic, G Fountzilas, F Coxon, E Díaz-Rubio, T S Maughan, A Malzyner, O Bertetto, A Beham, A Figer, P Dufour, K K Patel, W Cowell and L P Garrison Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial doi:10.1038/sj.bjc.6603059 Abstract | Full article | PDF M E Burge, D Smith, C Topham, D P Jackson, D A Anthoney, F Halstead and M T Seymour A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma advance online publication, 2006-04-11 00:00:00.000; doi:10.1038/sj.bjc.6603084 Abstract | Full article | PDF J H Baek, J G Kim, S B Jeon, Y S Chae, D H Kim, S K Sohn, K B Lee, Y J Choi, H J Shin, J S Chung, G J Cho, H Y Jung and W Yu Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer advance online publication, 2006-04-25 00:00:00.000; doi:10.1038/sj.bjc.6603093 Abstract | Full article | PDF S E Ward, E Kaltenthaler, J Cowan, M Marples, B Orr and M T Seymour The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer doi:10.1038/sj.bjc.6603215 Abstract | Full article | PDF F Willeke, K Horisberger, U Kraus-Tiefenbacher, F Wenz, A Leitner, A Hochhaus, R Grobholz, A Willer, G Kähler, S Post and R-D Hofheinz A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer advance online publication, 2007-02-27 00:00:00.000; doi:10.1038/sj.bjc.6603645 Abstract | Full article | PDF E van Meerten, F A L M Eskens, E C van Gameren, L Doorn and A van der Gaast First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study advance online publication, 2007-04-17 00:00:00.000; doi:10.1038/sj.bjc.6603750 Abstract | Full article | PDF S C Oh, H Y Sur, H J Sung, I K Choi, S S Park, J H Seo, Y T Jeen, H J Chun, S W Shin, Y J Mok, J S Kim and Y H Kim A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer advance online publication, 2007-05-01 00:00:00.000; doi:10.1038/sj.bjc.6603752 Abstract | Full article | PDF V Boige, J-L Raoul, J-P Pignon, O Bouché, J-F Blanc, L Dahan, J-L Jouve, N Dupouy and M Ducreux Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial advance online publication, 2007-09-18 00:00:00.000; doi:10.1038/sj.bjc.6603956 Abstract | Full article | PDF E P M Jansen, H Boot, R Dubbelman, H Bartelink, A Cats and M Verheij Postoperative chemoradiotherapy in gastric cancer – a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy doi:10.1038/sj.bjc.6603965 Abstract | Full article | PDF I Craven, A Crellin, R Cooper, A Melcher, P Byrne and D Sebag-Montefiore Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer advance online publication, 2007-11-06 00:00:00.000; doi:10.1038/sj.bjc.6604042 Abstract | Full article | PDF T Ernst, K Merx, U Gnad-Vogt, N Lukan, M Kripp, B Schultheis, A Hochhaus and R-D Hofheinz Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial advance online publication, 2007-11-13 00:00:00.000; doi:10.1038/sj.bjc.6604067 Abstract | Full article | PDF O Nehls, H Oettle, J T Hartmann, R-D Hofheinz, H G Hass, M S Horger, U Koppenhöfer, A Hochhaus, J Stieler, J Trojan, M Gregor and B Klump Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial advance online publication, 2008-01-08 00:00:00.000; doi:10.1038/sj.bjc.6604178 Abstract | Full article | PDF H J Kang, H M Chang, T W Kim, M-H Ryu, H-J Sohn, J H Yook, S T Oh, B S Kim, J-S Lee and Y-K Kang A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer advance online publication, 2008-01-22 00:00:00.000; doi:10.1038/sj.bjc.6604186 Abstract | Full article | PDF D Koeberle, R Burkhard, R von Moos, R Winterhalder, V Hess, F Heitzmann, T Ruhstaller, L Terraciano, J Neuweiler, G Bieri, C Rust and M Toepfer Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer advance online publication, 2008-03-18 00:00:00.000; doi:10.1038/sj.bjc.6604297 Abstract | Full article | PDF W S Siegel-Lakhai, A S Zandvliet, A D R Huitema, M M Tibben, G Milano, V Girre, V Diéras, A King, E Richmond, J Wanders, J H Beijnen and J H M Schellens A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours advance online publication, 2008-04-15 00:00:00.000; doi:10.1038/sj.bjc.6604300 Abstract | Full article | PDF A L Farquharson, N Pranesh, G Witham, R Swindell, M B Taylor, A G Renehan, S Rout, M S Wilson, S T O'Dwyer and M P Saunders A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei advance online publication, 2008-08-05 00:00:00.000; doi:10.1038/sj.bjc.6604522 Abstract | Full article | PDF J-L Lee, Y-K Kang, H J Kang, K-H Lee, D Y Zang, B-Y Ryoo, J G Kim, S R Park, W K Kang, D B Shin, M-H Ryu, H M Chang, T-W Kim, J H Baek and Y J Min A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer advance online publication, 2008-07-29 00:00:00.000; doi:10.1038/sj.bjc.6604536 Abstract | Full article | PDF K R Schønnemann, H A Jensen, M Yilmaz, B V Jensen, O Larsen and P Pfeiffer Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer advance online publication, 2008-08-26 00:00:00.000; doi:10.1038/sj.bjc.6604569 Abstract | Full article | PDF D M Kweekel, M Koopman, N F Antonini, T Van der Straaten, J W R Nortier, H Gelderblom, C J A Punt and H-J Guchelaar GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group advance online publication, 2008-09-16 00:00:00.000; doi:10.1038/sj.bjc.6604654 Abstract | Full article | PDF L C Pronk, P Vasey, A Sparreboom, B Reigner, A S Th Planting, R J Gordon, B Osterwalder, J Verweij and C Twelves A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours doi:10.1054/bjoc.2000.1160 Abstract | Full article | PDF K Oevermann, J Buer, R Hoffmann, A Franzke, A Schrader, T Patzelt, H Kirchner and J Atzpodien Capecitabine in the treatment of metastatic renal cell carcinoma doi:10.1054/bjoc.2000.1340 Abstract | Full article | PDF R C F Leonard Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer doi:10.1054/bjoc.2001.1819 Abstract | Full article | PDF |
||||||||
| capillary Y Yasuda, T Musha, H Tanaka, Y Fujita, H Fujita, H Utsumi, T Matsuo, S Masuda, M Nagao, R Sasaki and Y Nakamura Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice doi:10.1054/bjoc.2000.1666 Abstract | Full article | PDF |
||||||||
| CAR M Kim, L A Sumerel, N Belousova, G R Lyons, D E Carey, V Krasnykh and J T Douglas The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells doi:10.1038/sj.bjc.6600932 Abstract | Full article | PDF |
||||||||
| carbogen E L Hull, D L Conover and T H Foster Carbogen-induced changes in rat mammary tumour oxygenation reported by near infrared spectroscopy doi:10.1038/sj.bjc.6690272 Abstract | Full article | PDF T J Dunn, R D Braun, W E Rhemus, G L Rosner, T W Secomb, G M Tozer, D J Chaplin and M W Dewhirst The effects of hyperoxic and hypercarbic gases on tumour blood flow doi:10.1038/sj.bjc.6690330 Abstract | Full article | PDF S P Robinson, F A Howe, M Stubbs and J R Griffiths Effects of nicotinamide and carbogen on tumour oxygenation, blood flow, energetics and blood glucose levels doi:10.1054/bjoc.2000.1144 Abstract | Full article | PDF |
||||||||
| carbohydrate J C Egrie and J K Browne Development and characterization of novel erythropoiesis stimulating protein (NESP) doi:10.1054/bjoc.2001.1746 Abstract | Full article | PDF |
||||||||
| carbohydrate antigen 15-3 B Nakata, T Takashima, Y Ogawa, T Ishikawa and K Hirakawa Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer advance online publication, 2004-07-27 00:00:00.000; doi:10.1038/sj.bjc.6602074 Abstract | Full article | PDF |
||||||||
| carbohydrate determinants K Kontani, O Taguchi, T Narita, M Izawa, N Hiraiwa, K Zenita, T Takeuchi, H Murai, S Miura and R Kannagi Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes doi:10.1054/bjoc.2000.1744 Abstract | Full article | PDF |
||||||||
| carbon dioxide T J Dunn, R D Braun, W E Rhemus, G L Rosner, T W Secomb, G M Tozer, D J Chaplin and M W Dewhirst The effects of hyperoxic and hypercarbic gases on tumour blood flow doi:10.1038/sj.bjc.6690330 Abstract | Full article | PDF |
||||||||
| carbonic acid K J Turner, J P Crew, C C Wykoff, P H Watson, R Poulsom, J Pastorek, P J Ratcliffe, D Cranston and A L Harris The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer doi:10.1038/sj.bjc.6600215 Abstract | Full article | PDF |
||||||||
| carbonic anhydrase P H Watson, S K Chia, C C Wykoff, C Han, R D Leek, W S Sly, K C Gatter, P Ratcliffe and A L Harris Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma doi:10.1038/sj.bjc.6600796 Abstract | Full article | PDF J Závada, Z Závadová, J Pastorek, Z Biesová, J Jez˘ek and J Velek Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion doi:10.1054/bjoc.2000.1111 Abstract | Full article | PDF |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
|
|
|
| |||
| Print ISSN: 0007-0920 | Online ISSN: 1532-1827 | © 2008 Cancer Research UK | ||
| |||
| Privacy Policy | |||